MAP2K7 and melanoma: IGF2BP1 could promote leukemia cell resistance to doxorubicin, cytarabine, and cyclophosphamide, and enhance melanoma cell resistance to dacarbazine, temozolomide, vinblastine, and etoposide168,213 Furthermore, IGF2BP1 desensitized BRAFV600E melanoma cells to vemurafenib, BRAF-inhibitors, and BRAF-MEK inhibitors, and CRC cells to 5-FU, irinotecan (CPT-11), and oxaliplatin.214